Can B CORP

Can B Corp. has completed a holding company reorganization, becoming a wholly-owned subsidiary of Nascent Pharma Holdings, with existing Can B shareholders receiving equivalent shares in Nascent.

Can B Corp. has decided to discontinue its hemp operations after an equipment auction and will incur costs related to lease termination and stock issuance.

Can B Corp. has engaged Haynie & Company as its new independent registered public accounting firm, effective May 28, 2024.

Can B Corp. has dismissed BF Borgers as its independent auditor, effective May 6, 2024, following concerns about the firm's ability to continue as a going concern and an SEC order restricting BF Borgers from practicing before the commission.

Can B Corp has finalized a $75,000 loan agreement with ClearThink Capital Partners, featuring a convertible note with a significant original issue discount.

Can B Corp has completed the auction of its hemp division assets for approximately $300,000, and will now focus on commercializing its recently acquired cannabis patents.

Can B Corp. announces its Q3 2024 results, marked by a strategic shift away from hemp operations towards commercializing cannabis patents, while facing significant financial headwinds.

Can B Corp. announces its Q2 2024 results and a strategic shift towards commercializing cannabis patents after discontinuing its hemp operations.

Can B Corp. files an amended Q1 2024 report to incorporate a review by a new auditor after the SEC suspended BF Borgers, revealing a net loss of $6.16 million and the discontinuation of hemp operations.

Can B Corp.'s Q1 2024 results reveal a net loss, decreased revenues, and ongoing legal battles, raising substantial doubt about the company's ability to continue as a going concern.

Can B Corp.'s 2023 annual report highlights a strategic shift towards commercializing newly acquired cannabis patents, following an auction of its hemp division assets and reduced performance in its durable medical equipment business.